With the development of imaging technology and the advent of new specific imaging agents, molecular imaging techniques represented by PET/CT are playing an increasingly important role in the precise diagnosis and treatment of malignant tumors, with Prostate-specific membrane antigen (PSMA) as a targeted molecule receiving much attention in prostate cancer diagnosis and treatment (6). This evidence concerns the gene FOLH1 and cancer.